Form D · Pharmaceuticals
Regenacy Pharmaceuticals, Inc.
Waltham, MA · CIK 0001807611
Offering snapshot reported Feb 10, 2022 · SEC filing
- Reported sold
- $7.81M Offering amount: $10M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 27, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 10, 2022 | Initial | $7,808,997 | No comparison | 9 | SEC filing |
| Apr 8, 2020 | Initial | $20,857,418 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-433023
Source: Form D, filed Feb 10, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Chin | Director |
| Marc Cohen | Director, Executive |
| Michael L. Huang | Director |
| Simon Jones | Director, Executive |
| John Rocha | Executive |
| Daguang Wang | Director |
| Shixiang Yan | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
303 Wyman Street, Suite 300
Waltham, MA, 02451
Waltham, MA, 02451